However, studies with patients and mouse models of glioblastoma and pancreatic cancer have shown that these types of cancer can be resistant or refractory to anti-VEGF signaling therapies [14], [16], [33], [35]–[37]. This evidence concerns the gene VEGFA and glioblastoma.